Middle East & Africa Non-Radiographic Axial Spondyloarthritis Therapeutics Market
Description
Middle East and Africa non-radiographic axial spondyloarthritis therapeutics market is expected to reach USD 593.28 million by 2033 from USD 321.86 million in 2025, growing at a substantial CAGR of 8.1% in the forecast period of 2026 to 2033.
Market Segmentation:
By Treatment Type (Medication, Surgery, Physical Therapy, and Others) By Drug (Adalimumab, Secukinumab, Etanercept, Ixekizumab, Upadacitinib, Certolizumab Pegol, Golimumab, Infliximab, Tofacitinib, and Others) By Route of Administration (Subcutaneous, Oral, Intravenous, and Others) By End User (Specialty Clinics, Homecare, Hospitals, Pharmacy & Retailers, and Others) By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Direct Tender, Online Pharmacy, and Others) By Country (Saudi Arabia, South Africa, U.A.E, Israel, Egypt, Kuwait, Qatar, Oman, Bahrain, and Rest of Middle East & Africa)-Industry Trends and Forecast to 2033.
Overview of the Middle East and Africa Non-Radiographic Axial Spondyloarthritis Therapeutics Market are:
Driver
• Growing adoption of biologics such as TNF inhibitors and IL-17 inhibitors for early-stage treatment.
• Advancements in diagnostic techniques enabling earlier and more accurate detection
• Rising healthcare expenditure and improved access to specialty care in emerging markets
• Increasing prevalence of non-radiographic axial spondyloarthritis and improved disease
• Awareness
Restrain
• High cost of biologic therapies limiting patient access in low- and middle-income regions
• Stringent regulatory approval processes for novel therapeutics delaying market entry
Opportunity
• Development of targeted therapies and novel biologics with improved efficacy and safety profiles
• Expansion of biosimilars market reducing treatment costs and improving accessibility
• Growing focus on personalized medicine and precision therapeutics
Market Players:
The key market players for Middle East and Africa non-radiographic axial spondyloarthritis therapeutics market are listed below:
• Novartis AG (Switzerland)
• Pfizer Inc. (U.S.)
• AbbVie Inc. (U.S.)
• UCB Group (Belgium)
• Eli Lilly and Company (U.S.)
• Biogen (U.S.)
• Johnson & Johnson (U.S.)
• Amgen Inc. (U.S.)
• Bristol-Myers Squibb (U.S.)
• Merck KGaA (Germany)
• Sanofi (France)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Boehringer Ingelheim (Germany)
• Astellas Pharma Inc. (Japan)
• Gedeon Richter Plc. (Hungary)
• Sun Pharmaceutical Industries Ltd (India)
• Lupin Limited (India)
• Dr. Reddy’s Laboratories Limited (India)
• Teva Pharmaceutical Industries Ltd (Israel)
• Zydus Group (India)
• Viatris Inc. (U.S.)
• Fresenius Kabi (Germany)
• Kyowa Kirin Co., Ltd (Japan)
• Celltrion Inc. (South Korea)
• Torrent Pharmaceuticals Ltd (India)
• Samsung Bioepis (South Korea)
• Alkem Laboratories (India)
• Cipla (India)
• Sandoz (Switzerland)
• Takeda Pharmaceutical Company Limited (Japan)
• Biocad (Russia)
Market Segmentation:
By Treatment Type (Medication, Surgery, Physical Therapy, and Others) By Drug (Adalimumab, Secukinumab, Etanercept, Ixekizumab, Upadacitinib, Certolizumab Pegol, Golimumab, Infliximab, Tofacitinib, and Others) By Route of Administration (Subcutaneous, Oral, Intravenous, and Others) By End User (Specialty Clinics, Homecare, Hospitals, Pharmacy & Retailers, and Others) By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Direct Tender, Online Pharmacy, and Others) By Country (Saudi Arabia, South Africa, U.A.E, Israel, Egypt, Kuwait, Qatar, Oman, Bahrain, and Rest of Middle East & Africa)-Industry Trends and Forecast to 2033.
Overview of the Middle East and Africa Non-Radiographic Axial Spondyloarthritis Therapeutics Market are:
Driver
• Growing adoption of biologics such as TNF inhibitors and IL-17 inhibitors for early-stage treatment.
• Advancements in diagnostic techniques enabling earlier and more accurate detection
• Rising healthcare expenditure and improved access to specialty care in emerging markets
• Increasing prevalence of non-radiographic axial spondyloarthritis and improved disease
• Awareness
Restrain
• High cost of biologic therapies limiting patient access in low- and middle-income regions
• Stringent regulatory approval processes for novel therapeutics delaying market entry
Opportunity
• Development of targeted therapies and novel biologics with improved efficacy and safety profiles
• Expansion of biosimilars market reducing treatment costs and improving accessibility
• Growing focus on personalized medicine and precision therapeutics
Market Players:
The key market players for Middle East and Africa non-radiographic axial spondyloarthritis therapeutics market are listed below:
• Novartis AG (Switzerland)
• Pfizer Inc. (U.S.)
• AbbVie Inc. (U.S.)
• UCB Group (Belgium)
• Eli Lilly and Company (U.S.)
• Biogen (U.S.)
• Johnson & Johnson (U.S.)
• Amgen Inc. (U.S.)
• Bristol-Myers Squibb (U.S.)
• Merck KGaA (Germany)
• Sanofi (France)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Boehringer Ingelheim (Germany)
• Astellas Pharma Inc. (Japan)
• Gedeon Richter Plc. (Hungary)
• Sun Pharmaceutical Industries Ltd (India)
• Lupin Limited (India)
• Dr. Reddy’s Laboratories Limited (India)
• Teva Pharmaceutical Industries Ltd (Israel)
• Zydus Group (India)
• Viatris Inc. (U.S.)
• Fresenius Kabi (Germany)
• Kyowa Kirin Co., Ltd (Japan)
• Celltrion Inc. (South Korea)
• Torrent Pharmaceuticals Ltd (India)
• Samsung Bioepis (South Korea)
• Alkem Laboratories (India)
• Cipla (India)
• Sandoz (Switzerland)
• Takeda Pharmaceutical Company Limited (Japan)
• Biocad (Russia)
Table of Contents
350 Pages
- 1 Introduction
- 1.1 Objectives Of The Study
- 1.2 Market Definition
- 1.3 Overview Of Middle East And Africa Non-radiographic Axial Spondyloarthritis Therapeutics Market
- 1.4 Limitations
- 1.5 Markets Covered
- 2 Market Segmentation
- 2.1 Markets Covered
- 2.2 Geographical Scope
- 2.3 Years Considered For The Study
- 2.4 Currency And Pricing
- 2.5 Dbmr Tripod Data Validation Model
- 2.6 Multivariate Modelling
- 2.7 Primary Interviews With Key Opinion Leaders
- 2.8 Dbmr Market Position Grid
- 2.9 Market End User Coverage Grid
- 2.10 Vendor Share Analysis
- 2.11 Secondary Sources
- 2.12 Assumptions
- 3 Executive Summary
- 4 Premium Insights
- 4.1 Porter’s Five Forces
- 4.1.1 Threat Of New Entrants
- 4.1.2 Threat Of Substitutes
- 4.1.3 Bargaining Power Of Buyers
- 4.1.4 Bargaining Power Of Suppliers
- 4.1.5 Industry Rivalry
- 4.2 Brand Outlook
- 4.3 Cost Analysis Breakdown
- 4.3.1 Drug Acquisition Costs And Pricing Dynamics
- 4.3.2 Manufacturing And Biologics Production Costs
- 4.3.3 Research And Development Expenditure
- 4.3.4 Distribution, Logistics, And Cold Chain Management
- 4.3.5 Administration And Healthcare System Costs
- 4.3.6 Impact Of Biosimilars And Competitive Pricing
- 4.3.7 Reimbursement Frameworks And Patient Access
- 4.3.8 Market Developments Influencing Cost Structures
- 4.3.9 Conclusion
- 4.4 Industry Ecosystem Analysis
- 4.4.1 Overview Of The Industry Ecosystem Structure
- 4.4.2 Drug Discovery And Translational Research Ecosystem
- 4.4.3 Clinical Development And Trial Infrastructure
- 4.4.4 Manufacturing And Biopharmaceutical Supply Chain Ecosystem
- 4.4.5 Regulatory And Health Authority Ecosystem
- 4.4.6 Healthcare Delivery And Prescribing Ecosystem
- 4.4.7 Distribution And Pharmaceutical Access Channels
- 4.4.8 Patient Advocacy And Disease Awareness Ecosystem
- 4.4.9 Pricing And Market Access Ecosystem
- 4.5 Innovation Tracker And Strategic Analysis
- 4.5.1 Major Deals And Strategic Alliances Analysis
- 4.5.1.1 Joint Ventures
- 4.5.1.2 Mergers And Acquisitions
- 4.5.1.3 Licensing And Partnership
- 4.5.1.4 Technology Collaborations
- 4.5.1.5 Strategic Divestments
- 4.5.2 Number Of Products In Development
- 4.5.3 Stage Of Development
- 4.5.4 Timelines And Milestones
- 4.5.5 Innovation Strategies And Methodologies
- 4.5.6 Risk Assessment And Mitigation
- 4.5.7 Future Outlook
- 4.6 Patent Analysis
- 4.6.1 Patent Quality And Strength
- 4.6.2 Country Patent Landscape.
- 4.6.3 Ip Strategy And Management
- 4.6.4 Licensing And Collaboration
- 4.7 Pricing Analysis
- 4.7.1 Premium Pricing Structure Dominated By Biologics And Targeted Therapies
- 4.7.2 Biologics As The Key Revenue And Price Realization Segment
- 4.7.3 Low-cost Volume Segment Led By Nsaids And Conventional Therapies
- 4.7.4 Regional Pricing Disparity Across Middle East And Africa Markets
- 4.7.5 Biosimilars Driving Downward Price Correction
- 4.7.6 Health Economic Burden And Payer-driven Pricing Pressure
- 4.8 Profit Margins Scenario
- 4.8.1 Overview Of Profit Margin Dynamics
- 4.8.2 Revenue Structure And Pricing Power In Biologic Therapies
- 4.8.3 Cost Structure And Manufacturing Economics
- 4.8.4 Impact Of Biosimilars And Competitive Erosion
- 4.8.5 Regional Reimbursement And Market Access Influence
- 4.8.6 Pipeline Innovation And Margin Expansion Potential
- 4.8.7 Regulatory Approvals And Market Expansion Context
- 4.8.8 Competitive And Clinical Adoption Dynamics
- 4.8.9 Innovation-driven Margin Sustainability
- 4.8.10 Conclusion
- 4.9 Raw Material Coverage
- 4.9.1 Overview Of Raw Material Landscape
- 4.9.2 Biologic Active Ingredient Production Inputs
- 4.9.3 Cell Culture Media And Upstream Processing Materials
- 4.9.4 Chromatography And Purification Materials
- 4.9.5 Formulation Excipients And Stabilization Agents
- 4.9.6 Primary Packaging Materials
- 4.9.7 Secondary Packaging And Cold Chain Logistics Materials
- 4.9.8 Quality Standards And Regulatory Material Compliance
- 4.9.9 Supply Chain Constraints And Risk Factors
- 4.9.10 Emerging Trends In Raw Material Innovation
- 4.10 Technological Advancements
- 4.10.1 Evolution Of Targeted Biologic Therapies
- 4.10.2 Emergence Of Il-17 Inhibitors And Novel Mechanistic Pathways
- 4.10.3 Advancement Of Oral Small Molecule Therapies
- 4.10.4 Biomarker-driven Diagnosis And Treatment Optimization
- 4.10.5 Digital Health Integration And Remote Monitoring
- 4.10.6 Advances In Drug Delivery Systems
- 4.10.7 Ongoing Research In Next-generation Therapeutics
- 4.10.8 Integration Of Precision Medicine Approaches
- 4.10.9 Conclusion
- 4.11 Value Chain Analysis
- 4.11.1 Raw Materials And Active Pharmaceutical Ingredients
- 4.11.2 Drug Discovery And Preclinical Development
- 4.11.3 Manufacturing And Bioprocessing
- 4.11.4 Processing, Fill-finish And Sterilization
- 4.11.5 Packaging And Labeling
- 4.11.6 Distribution And Logistics
- 4.11.7 Conclusion
- 4.12 Vendor Selection Criteria
- 4.12.1 Clinical Efficacy And Evidence-based Differentiation
- 4.12.2 Mechanism Of Action And Portfolio Breadth
- 4.12.3 Regulatory Compliance And Middle East And Africa Market Access
- 4.12.4 Pricing Strategy And Reimbursement Landscape
- 4.12.5 Manufacturing Capabilities And Supply Chain Reliability
- 4.12.6 Strategic Collaborations And Innovation Capacity
- 4.12.7 Real-world Evidence And Post-marketing Surveillance
- 4.12.8 Market Presence And Physician Engagement
- 4.12.9 Conclusion
- 5 Tariffs & Impact On The Market
- 5.1 Current Tariff Rate(S) In Top-5 Country Markets
- 5.2 Outlook: Local Production Versus Import Reliance
- 5.3 Vendor Selection Criteria Dynamics
- 5.4 Impact On Supply Chain
- 5.4.1 Raw Material Procurement
- 5.4.2 Manufacturing And Production
- 5.4.3 Logistics And Distribution
- 5.4.4 Price Pitching And Market Position
- 5.5 Industry Participants: Proactive Moves
- 5.5.1 Supply Chain Optimization
- 5.5.2 Joint Venture Establishments
- 6 Regulatory Framework And Approval Pathways
- 6.1 Overview
- 6.2 Regional Regulatory And Reimbursement Landscapes
- 6.3 Pricing, Health Technology Assessment And Coverage
- 6.4 Post-marketing Surveillance And Pharmacovigilance
- 7 Market Overview
- 7.1 Driver
- 7.1.1 Increasing Prevalence Of Non-radiographic Axial Spondyloarthritis And Improved Disease Awareness
- 7.1.2 Growing Adoption Of Biologics Such As Tnf Inhibitors And Il-17 Inhibitors For Early-stage Treatment
- 7.1.3 Advancements In Diagnostic Techniques Enabling Earlier And More Accurate Detection
- 7.1.4 Rising Healthcare Expenditure And Improved Access To Specialty Care In Emerging Markets
- 7.2 Restraint
- 7.2.1 High Cost Of Biologic Therapies Limiting Patient Access In Low- And Middle-income Regions
- 7.2.2 Stringent Regulatory Approval Processes For Novel Therapeutics Delaying Market Entry
- 7.3 Opportunities
- 7.3.1 Development Of Targeted Therapies And Novel Biologics With Improved Efficacy And Safety Profiles
- 7.3.2 Expansion Of Biosimilars Market Reducing Treatment Costs And Improving Accessibility
- 7.3.3 Growing Focus On Personalized Medicine And Precision Therapeutics
- 7.4 Challenges
- 7.4.1 Complexity In Disease Diagnosis Due To Lack Of Radiographic Evidence In Early Stages
- 7.4.2 Patient Adherence Issues Due To Chronic Nature Of Treatment
- 8 Middle East And Africa Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Treatment Type
- 8.1 Overview
- 8.2 Middle East And Africa Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Region, 2018-2033 (Usd Thousand)
- 8.2.1 North America
- 8.2.2 Europe
- 8.2.3 Asia-pacific
- 8.2.4 South America
- 8.2.5 Middle East & Africa
- 8.3 Middle East And Africa Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Treatment Type, 2018-2033 (Usd Thousand)
- 8.3.1 Medication
- 8.3.2 Surgery
- 8.3.3 Physical Therapy
- 8.3.4 Others
- 8.4 Middle East And Africa Medication In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Type, 2018-2033 (Usd Thousand)
- 8.4.1 Biologics
- 8.4.2 Nsaids
- 8.4.3 Analgesics
- 8.4.4 Disease-modifying Antirheumatic Drugs (Dmards)
- 8.4.5 Others
- 8.5 Middle East And Africa Biologics In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Type, 2018-2033 (Usd Thousand)
- 8.5.1 Tnf Inhibitors
- 8.5.2 Interleukin (Il-17) Inhibitors
- 8.5.3 Jak Inhibitors
- 8.5.4 Others
- 8.6 Middle East And Africa Tnf Inhibitors In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Type, 2018-2033 (Usd Thousand)
- 8.6.1 Adalimumab
- 8.6.2 Etanercept
- 8.6.3 Certolizumab Pegol
- 8.6.4 Infliximab
- 8.6.5 Others
- 8.7 Middle East And Africa Interleukin (Il-17) Inhibitors In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Type, 2018-2033 (Usd Thousand)
- 8.7.1 Secukinumab
- 8.7.2 Ixekizumab
- 8.7.3 Others
- 8.8 Middle East And Africa Jak Inhibitors In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Type, 2018-2033 (Usd Thousand)
- 8.8.1 Upadacitinib
- 8.8.2 Tofacitinib
- 8.8.3 Others
- 8.9 Middle East And Africa Nsaids In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Type, 2018-2033 (Usd Thousand)
- 8.9.1 Traditional Nsaids
- 8.9.2 Selective Cox-2 Inhibitors
- 8.9.3 Others
- 8.10 Middle East And Africa Medication In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Region, 2018-2033 (Usd Thousand)
- 8.10.1 North America
- 8.10.2 Europe
- 8.10.3 Asia-pacific
- 8.10.4 South America
- 8.10.5 Middle East And Africa
- 8.11 Middle East And Africa Surgery In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Type, 2018-2033 (Usd Thousand)
- 8.11.1 Joint Replacement
- 8.11.2 Spinal Fusion
- 8.11.3 Others
- 8.12 Middle East And Africa Surgery In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Region, 2018-2033 (Usd Thousand)
- 8.12.1 North America
- 8.12.2 Europe
- 8.12.3 Asia-pacific
- 8.12.4 South America
- 8.12.5 Middle East And Africa
- 8.13 Middle East And Africa Physical Therapy In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Type, 2018-2033 (Usd Thousand)
- 8.13.1 Exercise-based Approaches
- 8.13.2 Hydrotherapy
- 8.13.3 Others
- 8.14 Middle East And Africa Physical Therapy In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Region, 2018-2033 (Usd Thousand)
- 8.14.1 North America
- 8.14.2 Europe
- 8.14.3 Asia-pacific
- 8.14.4 South America
- 8.14.5 Middle East And Africa
- 8.15 Middle East And Africa Other In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Region, 2018-2033 (Usd Thousand)
- 8.15.1 North America
- 8.15.2 Europe
- 8.15.3 Asia-pacific
- 8.15.4 South America
- 8.15.5 Middle East And Africa
- 9 Middle East And Africa Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Drug
- 9.1 Overview
- 9.2 Middle East And Africa Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Drug, 2018-2033 (Usd Thousand)
- 9.2.1 Adalimumab
- 9.2.2 Secukinumab
- 9.2.3 Etanercept
- 9.2.4 Ixekizumab
- 9.2.5 Upadacitinib
- 9.2.6 Certolizumab Pegol
- 9.2.7 Golimumab
- 9.2.8 Infliximab
- 9.2.9 Tofacitinib
- 9.2.10 Others
- 9.3 Middle East And Africa Adalimumab In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Region, 2018-2033 (Usd Thousand)
- 9.3.1 North America
- 9.3.2 Europe
- 9.3.3 Asia-pacific
- 9.3.4 South America
- 9.3.5 Middle East And Africa
- 9.4 Middle East And Africa Secukinumab In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Region, 2018-2033 (Usd Thousand)
- 9.4.1 North America
- 9.4.2 Europe
- 9.4.3 Asia-pacific
- 9.4.4 South America
- 9.4.5 Middle East And Africa
- 9.5 Middle East And Africa Etanercept In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Region, 2018-2033 (Usd Thousand)
- 9.5.1 North America
- 9.5.2 Europe
- 9.5.3 Asia-pacific
- 9.5.4 South America
- 9.5.5 Middle East And Africa
- 9.6 Middle East And Africa Ixekizumab In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Region, 2018-2033 (Usd Thousand)
- 9.6.1 North America
- 9.6.2 Europe
- 9.6.3 Asia-pacific
- 9.6.4 South America
- 9.6.5 Middle East And Africa
- 9.7 Middle East And Africa Upadacitinib In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Region, 2018-2033 (Usd Thousand)
- 9.7.1 North America
- 9.7.2 Europe
- 9.7.3 Asia-pacific
- 9.7.4 South America
- 9.7.5 Middle East And Africa
- 9.8 Middle East And Africa Certolizumab Pegol In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Region, 2018-2033 (Usd Thousand)
- 9.8.1 North America
- 9.8.2 Europe
- 9.8.3 Asia-pacific
- 9.8.4 South America
- 9.8.5 Middle East And Africa
- 9.9 Middle East And Africa Golimumab In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Region, 2018-2033 (Usd Thousand)
- 9.9.1 North America
- 9.9.2 Europe
- 9.9.3 Asia-pacific
- 9.9.4 South America
- 9.9.5 Middle East And Africa
- 9.10 Middle East And Africa Infliximab In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Region, 2018-2033 (Usd Thousand)
- 9.10.1 North America
- 9.10.2 Europe
- 9.10.3 Asia-pacific
- 9.10.4 South America
- 9.10.5 Middle East And Africa
- 9.11 Middle East And Africa Tofacitinib In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Region, 2018-2033 (Usd Thousand)
- 9.11.1 North America
- 9.11.2 Europe
- 9.11.3 Asia-pacific
- 9.11.4 South America
- 9.11.5 Middle East And Africa
- 9.12 Middle East And Africa Other In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Region, 2018-2033 (Usd Thousand)
- 9.12.1 North America
- 9.12.2 Europe
- 9.12.3 Asia-pacific
- 9.12.4 South America
- 9.12.5 Middle East And Africa
- 10 Middle East And Africa Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Route Of Administration
- 10.1 Overview
- 10.2 Middle East And Africa Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Route Of Administration, 2018-2033 (Usd Thousand)
- 10.2.1 Subcutaneous
- 10.2.2 Oral
- 10.2.3 Intravenous
- 10.2.4 Others
- 10.3 Middle East And Africa Subcutaneous In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Region, 2018-2033 (Usd Thousand)
- 10.3.1 North America
- 10.3.2 Europe
- 10.3.3 Asia-pacific
- 10.3.4 South America
- 10.3.5 Middle East And Africa
- 10.4 Middle East And Africa Oral In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Region, 2018-2033 (Usd Thousand)
- 10.4.1 North America
- 10.4.2 Europe
- 10.4.3 Asia-pacific
- 10.4.4 South America
- 10.4.5 Middle East And Africa
- 10.5 Middle East And Africa Intravenous In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Region, 2018-2033 (Usd Thousand)
- 10.5.1 North America
- 10.5.2 Europe
- 10.5.3 Asia-pacific
- 10.5.4 South America
- 10.5.5 Middle East And Africa
- 10.6 Middle East And Africa Others In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Region, 2018-2033 (Usd Thousand)
- 10.6.1 North America
- 10.6.2 Europe
- 10.6.3 Asia-pacific
- 10.6.4 South America
- 10.6.5 Middle East And Africa
- 11 Middle East And Africa Non-radiographic Axial Spondyloarthritis Therapeutics Market, By End User
- 11.1 Overview
- 11.2 Middle East And Africa Non-radiographic Axial Spondyloarthritis Therapeutics Market, By End User, 2018-2033 (Usd Thousand)
- 11.2.1 Specialty Clinics
- 11.2.2 Homecare
- 11.2.3 Hospitals
- 11.2.4 Pharmacy & Retailers
- 11.2.5 Others
- 11.3 Middle East And Africa Specialty Clinics In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Region, 2018-2033 (Usd Thousand)
- 11.3.1 North America
- 11.3.2 Europe
- 11.3.3 Asia-pacific
- 11.3.4 South America
- 11.3.5 Middle East And Africa
- 11.4 Middle East And Africa Homecare In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Region, 2018-2033 (Usd Thousand)
- 11.4.1 North America
- 11.4.2 Europe
- 11.4.3 Asia-pacific
- 11.4.4 South America
- 11.4.5 Middle East And Africa
- 11.5 Middle East And Africa Hospitals In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Region, 2018-2033 (Usd Thousand)
- 11.5.1 North America
- 11.5.2 Europe
- 11.5.3 Asia-pacific
- 11.5.4 South America
- 11.5.5 Middle East And Africa
- 11.6 Middle East And Africa Pharmacy & Retailers In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Region, 2018-2033 (Usd Thousand)
- 11.6.1 North America
- 11.6.2 Europe
- 11.6.3 Asia-pacific
- 11.6.4 South America
- 11.6.5 Middle East And Africa
- 11.7 Middle East And Africa Others In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Region, 2018-2033 (Usd Thousand)
- 11.7.1 North America
- 11.7.2 Europe
- 11.7.3 Asia-pacific
- 11.7.4 South America
- 11.7.5 Middle East And Africa
- 12 Middle East And Africa Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Distribution Channel
- 12.1 Overview
- 12.2 Middle East And Africa Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Distribution Channel, 2018-2033 (Usd Thousand)
- 12.2.1 Hospital Pharmacy
- 12.2.2 Retail Pharmacy
- 12.2.3 Direct Tender
- 12.2.4 Online Pharmacy
- 12.2.5 Others
- 12.3 Middle East And Africa Hospital Pharmacy In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Region, 2018-2033 (Usd Thousand)
- 12.3.1 North America
- 12.3.2 Europe
- 12.3.3 Asia-pacific
- 12.3.4 South America
- 12.3.5 Middle East And Africa
- 12.4 Middle East And Africa Retail Pharmacy In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Region, 2018-2033 (Usd Thousand)
- 12.4.1 North America
- 12.4.2 Europe
- 12.4.3 Asia-pacific
- 12.4.4 South America
- 12.4.5 Middle East And Africa
- 12.5 Middle East And Africa Direct Tender In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Region, 2018-2033 (Usd Thousand)
- 12.5.1 North America
- 12.5.2 Europe
- 12.5.3 Asia-pacific
- 12.5.4 South America
- 12.5.5 Middle East And Africa
- 12.6 Middle East And Africa Online Pharmacy In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Region, 2018-2033 (Usd Thousand)
- 12.6.1 North America
- 12.6.2 Europe
- 12.6.3 Asia-pacific
- 12.6.4 South America
- 12.6.5 Middle East And Africa
- 12.7 Middle East And Africa Others In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Region, 2018-2033 (Usd Thousand)
- 12.7.1 North America
- 12.7.2 Europe
- 12.7.3 Asia-pacific
- 12.7.4 South America
- 12.7.5 Middle East And Africa
- 13 Middle East And Africa Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Region
- 13.1 Middle East And Africa
- 13.1.1 Saudi Arabia
- 13.1.2 South Africa
- 13.1.3 U.A.E
- 13.1.4 Israel
- 13.1.5 Egypt
- 13.1.6 Kuwait
- 13.1.7 Qatar
- 13.1.8 Oman
- 13.1.9 Bahrain
- 13.1.10 Rest Of Middle East & Africa
- 14 Middle East And Africa Non-radiographic Axial Spondyloarthritis Therapeutics Market: Company Landscape
- 14.1 Company Share Analysis: Global
- 15 Swot Analysis
- 16 Company Profile Manufracturer
- 16.1 Novartis Ag
- 16.1.1 Company Snapshot
- 16.1.2 Revenue Analysis
- 16.1.3 Company Share Analysis
- 16.1.4 Product Portfolio
- 16.1.5 Recent Development
- 16.2 Pfizer Inc.
- 16.2.1 Company Snapshot
- 16.2.2 Revenue Analysis
- 16.2.3 Company Share Analysis
- 16.2.4 Product Portfolio
- 16.2.5 Recent Development
- 16.3 Abbvie Inc.
- 16.3.1 Company Snapshot
- 16.3.2 Revenue Analysis
- 16.3.3 Company Share Analysis
- 16.3.4 Product Portfolio
- 16.3.5 Recent Development
- 16.4 Ucb S.A.
- 16.4.1 Company Snapshot
- 16.4.2 Revenue Analysis
- 16.4.3 Company Share Analysis
- 16.4.4 Product Portfolio
- 16.4.5 Recent Development
- 16.5 Lilly
- 16.5.1 Company Snapshot
- 16.5.2 Revenue Analysis
- 16.5.3 Company Share Analysis
- 16.5.4 Product Portfolio
- 16.5.5 Recent Development
- 16.6 Biogen
- 16.6.1 Company Snapshot
- 16.6.2 Revenue Analysis
- 16.6.3 Product Portfolio
- 16.6.4 Recent Development
- 16.7 Alkem
- 16.7.1 Company Snapshot
- 16.7.2 Revenue Analysis
- 16.7.3 Product Portfolio
- 16.7.4 Recent Development
- 16.8 Amgen Inc.
- 16.8.1 Company Snapshot
- 16.8.2 Revenue Analysis
- 16.8.3 Product Portfolio
- 16.8.4 Recent Development
- 16.9 Astellas Pharma Inc
- 16.9.1 Company Snapshot
- 16.9.2 Revenue Analysis
- 16.9.3 Product Portfolio
- 16.9.4 Recent Development
- 16.10 Biocad
- 16.10.1 Company Snapshot
- 16.10.2 Product Portfolio
- 16.10.3 Recent Development
- 16.11 Boehringer Ingelheim International Gmbh.
- 16.11.1 Company Snapshot
- 16.11.2 Product Portfolio
- 16.11.3 Recent Development
- 16.12 Bristol-myers Squibb (Bms)
- 16.12.1 Company Snapshot
- 16.12.2 Revenue Analysis
- 16.12.3 Product Portfolio
- 16.12.4 Recent Development
- 16.13 Celltrion Inc.
- 16.13.1 Company Snapshot
- 16.13.2 Revenue Analysis
- 16.13.3 Product Portfolio
- 16.13.4 Recent Developments
- 16.14 Cipla
- 16.14.1 Company Snapshot
- 16.14.2 Revenue Analysis
- 16.14.3 Product Portfolio
- 16.14.4 Recent Developments
- 16.15 Dr.Reddy’s Laboratories Ltd.
- 16.15.1 Company Snapshot
- 16.15.2 Revenue Analysis
- 16.15.3 Product Portfolio
- 16.15.4 Recent Developments
- 16.16 F. Hoffmann-la Roche Ltd
- 16.16.1 Company Snapshot
- 16.16.2 Revenue Analysis
- 16.16.3 Product Portfolio
- 16.16.4 Recent Development
- 16.17 Fresenius Se & Co. Kgaa
- 16.17.1 Company Snapshot
- 16.17.2 Revenue Analysis
- 16.17.3 Product Portfolio
- 16.17.4 Recent Development
- 16.18 Gedeon Richter Plc.
- 16.18.1 Company Snapshot
- 16.18.2 Revenue Analysis
- 16.18.3 Product Portfolio
- 16.18.4 Recent Developments
- 16.19 Johnson & Johnson And Its Affiliates
- 16.19.1 Company Snapshot
- 16.19.2 Revenue Analysis
- 16.19.3 Product Portfolio
- 16.19.4 Recent Development
- 16.20 Kyowa Kirin Co., Ltd.
- 16.20.1 Company Snapshot
- 16.20.2 Revenue Analysis
- 16.20.3 Product Portfolio
- 16.20.4 Recent Development
- 16.21 Lupin
- 16.21.1 Company Snapshot
- 16.21.2 Revenue Analysis
- 16.21.3 Product Portfolio
- 16.21.4 Recent Developments
- 16.22 Merck Kgaa
- 16.22.1 Company Snapshot
- 16.22.2 Revenue Analysis
- 16.22.3 Product Portfolio
- 16.22.4 Recent Development
- 16.23 Samsung Bioepis
- 16.23.1 Company Snapshot
- 16.23.2 Product Portfolio
- 16.23.3 Recent Development
- 16.24 Sandoz.Inc
- 16.24.1 Company Snapshot
- 16.24.2 Revenue Analysis
- 16.24.3 Product Portfolio
- 16.24.4 Recent Development
- 16.25 Sanofi
- 16.25.1 Company Snapshot
- 16.25.2 Revenue Analysis
- 16.25.3 Product Portfolio
- 16.25.4 Recent Development
- 16.26 Sun Pharmaceutical Industries Ltd.
- 16.26.1 Company Snapshot
- 16.26.2 Revenue Analysis
- 16.26.3 Product Portfolio
- 16.26.4 Recent Developments
- 16.27 Takeda Pharmaceutical Company Limited.
- 16.27.1 Company Snapshot
- 16.27.2 Revenue Analysis
- 16.27.3 Product Portfolio
- 16.27.4 Recent Development
- 16.28 Teva Pharmaceutical Industries Ltd.
- 16.28.1 Company Snapshot
- 16.28.2 Revenue Analysis
- 16.28.3 Product Portfolio
- 16.28.4 Recent Development
- 16.29 Torrent Pharmaceuticals Ltd.
- 16.29.1 Company Snapshot
- 16.29.2 Revenue Analysis
- 16.29.3 Product Portfolio
- 16.29.4 Recent Developments
- 16.30 Viatris Inc.
- 16.30.1 Company Snapshot
- 16.30.2 Revenue Analysis
- 16.30.3 Product Portfolio
- 16.30.4 Recent Developments
- 16.31 Zydus Group
- 16.31.1 Company Snapshot
- 16.31.2 Revenue Analysis
- 16.31.3 Product Portfolio
- 16.31.4 Recent Development
- 17 Company Profile Distributor
- 17.1 Alfresa Pharma Corporation
- 17.1.1 Company Snapshot
- 17.1.2 Revenue Analysis
- 17.1.3 Product Portfolio
- 17.1.4 Recent Development
- 17.2 Astute Healthcare Ltd.
- 17.2.1 Company Snapshot
- 17.2.2 Product Portfolio
- 17.2.3 Recent Development
- 17.3 Cardinal Health
- 17.3.1 Company Snapshot
- 17.3.2 Revenue Analysis
- 17.3.3 Product Portfolio
- 17.3.4 Recent Development
- 17.4 Cencora, Inc.
- 17.4.1 Company Snapshot
- 17.4.2 Revenue Analysis
- 17.4.3 Product Portfolio
- 17.4.4 Recent Development
- 17.5 Mckesson Corporation
- 17.5.1 Company Snapshot
- 17.5.2 Revenue Analysis
- 17.5.3 Product Portfolio
- 17.5.4 Recent Development
- 17.6 Medipal Holdings Corporation
- 17.6.1 Company Snapshot
- 17.6.2 Revenue Analysis
- 17.6.3 Product Portfolio
- 17.6.4 Recent Development
- 17.7 Phoenix Pharma Se
- 17.7.1 Company Snapshot
- 17.7.2 Product Portfolio
- 17.7.3 Recent Development
- 17.8 Smith Drug Company
- 17.8.1 Company Snapshot
- 17.8.2 Product Portfolio
- 17.8.3 Recent Development
- 17.9 Zuellig Pharma
- 17.9.1 Company Snapshot
- 17.9.2 Product Portfolio
- 17.9.3 Recent Development
- 18 Questionnaire
- 19 Related Reports
- List Of Tables
- Table 1 Cost Breakdown (Biologic Vs Non-biologic Therapy)
- Table 2 Drug Cost Benchmarks (Middle East And Africa Pricing Perspective)
- Table 3 Middle East And Africa Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Region, 2018-2033 (Usd Thousand)
- Table 4 Middle East And Africa Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Treatment Type, 2018-2033 (Usd Thousand)
- Table 5 Middle East And Africa Medication In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Type, 2018-2033 (Usd Thousand)
- Table 6 Middle East And Africa Biologics In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Type, 2018-2033 (Usd Thousand)
- Table 7 Middle East And Africa Tnf Inhibitors In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Type, 2018-2033 (Usd Thousand)
- Table 8 Middle East And Africa Interleukin (Il-17) Inhibitors In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Type, 2018-2033 (Usd Thousand)
- Table 9 Middle East And Africa Jak Inhibitors In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Type, 2018-2033 (Usd Thousand)
- Table 10 Middle East And Africa Nsaids In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Type, 2018-2033 (Usd Thousand)
- Table 11 Middle East And Africa Medication In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Region, 2018-2033 (Usd Thousand)
- Table 12 Middle East And Africa Surgery In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Type, 2018-2033 (Usd Thousand)
- Table 13 Middle East And Africa Surgery In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Region, 2018-2033 (Usd Thousand)
- Table 14 Middle East And Africa Physical Therapy In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Type, 2018-2033 (Usd Thousand)
- Table 15 Middle East And Africa Physical Therapy In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Region, 2018-2033 (Usd Thousand)
- Table 16 Middle East And Africa Other In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Region, 2018-2033 (Usd Thousand)
- Table 17 Middle East And Africa Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Drug, 2018-2033 (Usd Thousand)
- Table 18 Middle East And Africa Adalimumab In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Region, 2018-2033 (Usd Thousand)
- Table 19 Middle East And Africa Secukinumab In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Region, 2018-2033 (Usd Thousand)
- Table 20 Middle East And Africa Etanercept In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Region, 2018-2033 (Usd Thousand)
- Table 21 Middle East And Africa Ixekizumab In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Region, 2018-2033 (Usd Thousand)
- Table 22 Middle East And Africa Upadacitinib In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Region, 2018-2033 (Usd Thousand)
- Table 23 Middle East And Africa Certolizumab Pegol In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Region, 2018-2033 (Usd Thousand)
- Table 24 Middle East And Africa Golimumab In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Region, 2018-2033 (Usd Thousand)
- Table 25 Middle East And Africa Infliximab In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Region, 2018-2033 (Usd Thousand)
- Table 26 Middle East And Africa Tofacitinib In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Region, 2018-2033 (Usd Thousand)
- Table 27 Middle East And Africa Other In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Region, 2018-2033 (Usd Thousand)
- Table 28 Middle East And Africa Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Route Of Administration, 2018-2033 (Usd Thousand)
- Table 29 Middle East And Africa Subcutaneous In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Region, 2018-2033 (Usd Thousand)
- Table 30 Middle East And Africa Oral In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Region, 2018-2033 (Usd Thousand)
- Table 31 Middle East And Africa Intravenous In Non-radiographic Axial Spondyloarthritis Therapeutics Market, By Region, 2018-2033 (Usd Thousand)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
